Should I Buy VMD? VMD 2026 Analysis

Should You Buy Viemed Healthcare Inc (VMD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

8.640

1 Day change

0.70%

52 Week Range

8.940

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

BUY right now. The tape is bullish (stacked moving averages and a strengthening MACD) and the statistical pattern outlook points to upside over the next month (+4.95%). While RSI is elevated and price is pressing near resistance, the broader trend is up and favors buying now rather than waiting for a perfect pullback.

Technical Analysis

Trend: Bullish. Price (7.685) is above the pivot (7.434) and above R1 (7.627), signaling strength. Moving averages are clearly bullish (SMA_5 > SMA_20 > SMA_200), consistent with an established uptrend. MACD histogram is positive (0.01) and expanding, supporting continued upward momentum. RSI_6 is 71.487 (elevated), which increases the odds of a near-term pause/pullback even inside an uptrend. Levels: Immediate resistance is R2 at 7.746 (price is close), then a breakout would open continuation. First support is R1/nearby 7.627 and pivot 7.434; below that S1 is 7.241. Net: momentum is up, but short-term is slightly stretched near resistance.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options positioning is extremely call-skewed on open interest (call OI 473 vs put OI 7; OI put/call = 0.01), implying bullish positioning/sentiment. However, options volume is effectively zero today (todays_volume 0; put and call volume 0), so this is more about existing positioning than fresh conviction. Implied volatility is very high (30D IV ~~120.7) and above historical volatility (~~26.66), suggesting the options market is pricing large moves; near-term premium is expensive and sentiment is speculative rather than steady accumulation.

Technical Summary

Sell

Buy

Positive Catalysts

Strong technical uptrend (bullish MA stack + positive/expanding MACD).
Pattern-based projection favors upside over the next month (+4.95%).
Strong top-line growth in the latest reported quarter (2025/Q3 revenue +23.98% YoY).
Options open-interest skew is strongly bullish (very low put/call OI ratio).

Neutral/Negative Catalysts

Short-term overextension risk: RSI_6 at ~71 and price sitting just below/near R2 (7.
raises odds of a near-term stall.
Profitability quality softened despite revenue growth (2025/Q3 net income -9.41% YoY, EPS -10% YoY, gross margin down ~2.93% YoY).
No news catalysts in the last week; continuation depends more on technicals than fresh event-driven drivers.
Options IV is very elevated versus realized volatility, reflecting expensive risk pricing and potentially jumpy sentiment.

Financial Performance

Latest quarter: 2025/Q3. Revenue rose to 71.914M (+23.98% YoY), showing strong growth. However, profitability weakened: net income fell to 3.513M (-9.41% YoY), EPS to 0.09 (-10% YoY), and gross margin slipped to 56.94% (-2.93% YoY). Overall: strong demand/top-line momentum, but margin/earnings compression is a key watch item.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data was provided, so a recent trend in upgrades/downgrades and Wall Street pros/cons view cannot be confirmed from the dataset.

Analyst Rating

Wall Street analysts forecast VMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VMD is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold